CreatorsPublishersAdvertisers
View more in
Medical & Biotech

Silverback Therapeutics Presents Initial Safety Data From Solid Tumor Combo Therapy Trial

Benzinga
Benzinga
 2021-09-16
https://img.particlenews.com/image.php?url=0HB7d3_0bxmLy4y00
  • Silverback Therapeutics Inc (NASDAQ: SBTX) has presented interim data from a Phase 1/1b study of SBT6050 as a monotherapy and in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab).
  • Data were shared at the 2021 European Society for Medical Oncology Congress (ESMO21).
  • As of August, 40 patients with advanced or metastatic HER2-expressing or amplified solid tumors were enrolled in the trial.
  • The most frequent treatment-related adverse events included injection site reactions, fever and chills, hypotension, nausea, vomiting, and fatigue.
  • These mainly were mild or moderate, and severe/serious adverse events were reported.
  • At higher dose levels, dose-limiting toxicities (DLTs) were observed, including Grade 3 hypotension, injection site reaction, fever, and hypoxia. These DLTs were resolved with supportive care.
  • Mild or moderate Cytokine release syndrome (CRS) was observed.
  • Early signals of anti-tumor activity were observed in a heavily pre-treated, heterogeneous population.
  • Among 18 evaluable patients, one with HER2 IHC 2+ NSCLC had a confirmed partial response maintained at the most recently available scan obtained at 36 weeks post-enrollment and eight weeks after discontinuing study treatment.
  • In addition, stable disease was reported in seven patients.
  • Price Action: SBTX shares traded lower by 13.80% at $14 premarket on the last check Thursday.
  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)

Comments / 0

Comments / 0